AbbVie sets up shop in Singapore

Share this article:

AbbVie is establishing roots in Asia. The drugmaker announced Thursday that it was investing $320 million to build the manufacturing facility in Singapore—its first manufacturing site in all of Asia. The site will be focused on emerging oncology and immunology products.

The company said in a statement it expects the site will be fully operational by 2019 and will employ around 250.

AbbVie split from Abbott Laboratories in January 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.